Siemens Healthcare Diagnostics, a global leader in clinical
diagnostics, provides healthcare professionals in hospital,
reference, and physician office laboratories and point-of-care
settings with the vital information required to accurately
diagnose, treat, and monitor patients. Our innovative portfolio of
performance-driven solutions and personalized customer care combine
to streamline workflow, enhance operational efficiency, and support
improved patient outcomes.
MicroScan is a trademark of Siemens Healthcare Diagnostics
Inc.
Not available for sale in the U.S.
Product availability may vary from country to country and is
subject to varying regulatory requirements. Please contact your
local representative for availability.
Order No. A91DX-MM-131348-GC1-4A00 11-2013 | All rights reserved
2013 Siemens Healthcare Diagnostics Inc.
Global Siemens Headquarters Siemens AG Wittelsbacherplatz 2
80333 Muenchen Germany
Global Siemens Healthcare Headquarters Siemens AG Healthcare
Sector Henkestrasse 127 91052 Erlangen Telephone: + 49 9131 84-0
Germany
www.siemens.com/healthcare
www.siemens.com/diagnostics
Your First Choice in Resistance DetectionMicroScan Gram Positive
Conventional Panels
www.siemens.com/microbiology
Answers for life.
For more than 30 years, MicroScan Systems have been exclusively
focused on ID/AST testing, offering unmatched experience,
expertise, and technical support to help guide physicians and
improve patient care. MicroScan Dried Overnight Gram Positive
Panels from Siemens now continue a tradition of quality and
innovation. They are designed to help keep your laboratory staff at
the forefront of identification and susceptibility testing and are
compatible with all MicroScan instruments. Provide clinically
relevant
identification from an extensive database of gram-positive
microorganisms
Detect inducible clindamycin resistance on all Staphylococcus
species (98.7% category agreement to reference method)
Enhance accuracy of MRSA detection using integrated cefoxitin
screen (98.7% category agreement to reference method)
Global Division Siemens Healthcare Diagnostics Inc. 511 Benedict
Avenue Tarrytown, NY 10591-5005 USA www.siemens.com/diagnostics
Versatility for your unique testing needs. Experience
flexibility and choice through dynamic MicroScan menu options
designed to streamline testing and help boost your efficiency.
Manage changing formulary needs
with a broad antimicrobic menu and more than 95 MicroScan panel
choices (available globally)
Select ID-only, AST-only, and ID/AST combination panels for
workflow flexibility
Utilize a one-panel format for all Siemens microbiology
instruments for simplified testing procedures and streamlined
workflow
Perform and interpret tests manually or on MicroScan
instrumentation
Aligns with most EUCAST guidelines
Stay ahead of emerging resistance the trusted way.
First-time accuracy The MicroScan system uses a growth-based,
non-ID-dependent direct testing method, which allows for better
detection of emerging resistance. The system does not rely on
historical data: It provides a real-time advantage for accuracy and
uses direct MIC* technology to detect emerging and low-level
resistance. This means fewer confirmatory tests are needed,
providing you with accurate results the first time. This
functionality aligns with most CLSI guidelines to improve detection
of resistance mechanisms without additional confirmation tests.
*Minimum inhibitory concentration
Panel Name Pos Staph Combo 30Pos Strep Combo 36
Pos Combo 35
Pos Combo 37
Pos Combo 38
Pos Combo 42
Pos BP Combo 32
Pos BP Combo 33 Pos MIC 31 Pos MIC 32 Pos MIC 33
SMN 10460351 10479096 10479093 10479102 10479103 10713829
10479094 10479106 10479099 10479107 10713828
Legacy Catalog Number B1016 135 B1016 154 B1016 151 B1016 160
B1016 161 B1016 174 B1016 152 B1016 164 B1016 157 B1016 165 B1016
173
Languages FR E, FR, NO E, FR, GR, NO, PL E, ES, GR, PL, PT E,
ES, GR, PL, PT DE, E, ES, FR, GR, IT, PL, PT, TR DE, E, GR, IT,
NO, PLDE, E, FR, GR,
IT, NO, PL E, FR, NODE, E, FR, GR,
IT, NO, PLDE, E, ES, FR, GR,
IT, PL, PT, TR Abbr. Antimicrobic Agent g/mL g/mL g/mL g/mL g/mL
g/mL g/mL g/mL g/mL g/mL g/mL Abbr.
Ak Amikacin 8 16 8 32 8 32 AkAug Amoxicillin/K Clavulanate 4/2
8/4 4/2 8/4 4/2 8/4 2/1 8/4 0.5/0.25 8/4 4/2 8/4 AugAm Ampicillin
0.12 8 1 8 1 8 0.25, 4 8 4 8 2 8 0.12 8 0.5 8 0.25, 4 8 AmAzi
Azithromycin 1 2 1 2 1 2 AziCpe Cefepime 4 8 CpeCft Cefotaxime 0.5,
16 0.5, 16 1 2 Cft
CfxS Cefoxitin Screen 4 4 4 4 4 4 4 4 4 4 CfxSCpt Ceftaroline
0.5 1 0.5 1 CptCrm Cefuroxime 4 8 CrmCf Cephalothin 8 16 CfC
Chloramphenicol 8 16 8 16 8 16 8 8 16 8 8 16 C
Cp Ciprofloxacin 0.5 2 0.5 2 0.5 2 1 2 1 2 0.5 1 0.5 1 1 2 CpCla
Clarithromycin 1 2 ClaCd Clindamycin 0.25 2 0.25 2 0.25 2 0.25 2
0.25 2 0.25 0.5, 2 0.25 0.5, 2 0.25 2 0.25 0.5, 2 0.25 2 Cd
Dap Daptomycin 1 4 1 4 0.5 4 0.25 4 1 4 1, 4 1 4 1 0.5 4 1 4
DapEtp Ertapenem 0.5 1 EtpE Erythromycin 1 8 0.25 4 0.5 2 0.5 4
0.25 4 0.5 4 1 2 1 2 0.25 4 1 2 0.5 4 E
Fos Fosfomycin 32 32 64 32 64 32 64 32 32 32 32 32 64 FosFA
Fusidic Acid 2, 16 2, 16 2, 16 2, 16 2 2 2 2 FAGm Gentamicin 1 4 1
4 1 4 1 2 1, 4 8 1 2 1 4 1 1 4 1 8 Gm
GmS Gentamicin Synergy Screen 500 500 500 500 500 500 500 500
500 GmSImp Imipenem 1 2 2 8 1 2 2 8 4 8 ImpICd Inducible
Clindamycin Test 4/0.5 4/0.5 4/0.5 4/0.5 4/0.5 4/0.5 4/0.5 4/0.5
4/0.5 4/0.5 ICdK Kanamycin 2 16 4 16 K
KS Kanamycin Synergy Screen 1,000 1,000 KSLvx Levofloxacin 1 4 1
4 1 4 1 4 1 4 1 4 1 2 0.5 4 1 2 1 4 LvxLin Lincomycin 1 8 1 8 1 8
LinLzd Linezolid 1 4 0.5 4 1 4 1 4 1 4 2 4 2 4 2 4 0.5 4 0.5 4 1 4
LzdMer Meropenem 28 MerMin Minocycline 1 1 8 MinMxf Moxifloxacin
0.5 2 0.5 1 0.5 1 0.5 1 0.5 2 0.5 1 0.5 1 MxfMup Mupirocin 4, 256 4
8, 256 4 8, 256 256 4 8, 256 4 8 4 8, 256 256 MupNt Netilmicin 2 4
NtFd Nitrofurantoin 32 64 64 64 32 64 32 64 32 64 32 64 64 64 64 32
64 Fd
Nxn Norfloxacin 4 8 4 8 NxnOfl Ofloxacin 1 4 0.5 4 OflOx
Oxacillin 0.25 2 0.25 2 0.25 2 0.25 2 0.25 2 0.25, 1 2 0.25 2 0.25
2 0.25 2 0.25 2 OxP Penicillin 0.25 1, 16 0.03,0.12 0.25,2
0.03,0.12 0.25,2 0.03,0.12 0.25 0.03,0.12 0.25,2,8 0.12 0.25 0.03
0.12, 8 0.12 0.25, 2 0.03 0.25, 2 0.03 0.25, 2 0.12 0.25, 8 P
Prs Pristinamycin 0.5 2 1 2 1 2 1 2 1 2 PrsRif Rifampin 0.5 1,
4, 16 0.5, 4, 16 1 2 0.5 2 1 2 1 2 0.5, 4 16 0.5 2 0.5 2 RifStS
Streptomycin Synergy Screen 1,000 1,000 1,000 1,000 1,000 1,000
1,000 1,000 1,000 StSSyn Synercid 0.25 2 1 4 1 4 1 4 1 4 1 4 1 4
0.5 4 1 4 1 4 SynTei Teicoplanin 1 8 1 8 2 8 1 8 1 8 2 16 1 8 2 8 1
8 1 8 1 16 TeiTe Tetracycline 4 8 1 8 1 2 1 2 1 8 1 8 1 2 1 2 1 8 1
2 1 8 TeTo Tobramycin 1 2 1 2 1, 4 8 1 1 4 1 8 ToT/S
Trimethoprim/Sulfamethoxazole 2/38, 8/152 1/19 2/38 1/19 4/76 1/19
4/76 2/38 4/76 2/38 4/76 1/19 4/76 1/19 4/76 1/19 4/76 2/38 4/76
T/SVa Vancomycin 1 8 1 8 0.5 8 0.5 8 0.25 8 1 16 0.5 8 0.5 8 1 8
0.25 8 0.25 16 Va
Total Antimicrobics/Panel 23 22 26 23 21 26 30 29 34 35 34
Panel DefinitionsPos Staph Combo: Provides gram-positive
identification and susceptibility results on one panel. Drug
selection provides staphylococci coverage, as well as urine and
systemic reporting. Pos Strep Combo: Provides gram-positive
identification and susceptibility results on one panel. Drug
selection provides streptococci coverage, as well as urine and
systemic reporting. Pos Combo: Provides gram-positive
identification and susceptibility results on one panel. Drug
selection provides both staphylococci and enterococci coverage, as
well as urine and systemic reporting.Pos BP Combo: Provides gram-
positive identification and susceptibility results on one panel.
Drug selection provides both staphylococci and enterococci
coverage, as well as urine and systemic reporting. Panel contains
shorter dilutions around the breakpoints, allowing for a broader
drug menu.Pos MIC: Provide gram-positive susceptibility results
only and longer dilution schemes for better detection of emerging
resistance. Drug selection provides both staphylococci and
enterococci coverage, as well as urine and systemic reporting.
Not for sale in the U.S., China, or Japan
Legend: DE German E English ES Spanish FR French GR Greek IT
Italian NO Norwegian PL Polish PT Portuguese TR Turkish
